DeepSeek Enhances Biopharma IND and NDA Processes with AI
In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in...
Company
Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug...
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...
CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America
CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development,...
MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...
MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...
FDA Clears sBLA for Eisai and Biogen’s Leqembi Maintenance Dosing
Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that the...
Jiangsu Yuyue Partners with Inogen for International Distribution and R&D
China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...
Guangzhou Innogen’s Efsubaglutide Alfa Approved by NMPA for Type 2 Diabetes
China-based Guangzhou Innogen Pharmaceutical Group Co., Ltd, a biopharma focused on metabolic diseases, has announced...
MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...
Novo Nordisk’s Amycretin Shows Promising Weight Loss Results in Phase Ib/IIa Study
Denmark – based pharmaceutical giant Novo Nordisk A / S (NYSE: NVO) has announced topline...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth...
Sinopharm Partners with Biogen for Comprehensive Service Agreement
China-based Sinopharm Group Co., Ltd (HKG: 1099) has entered into a strategic partnership with US-based...
Boehringer Ingelheim’s Nerandomilast Granted Priority Review for IPF in China
German pharmaceutical giant Boehringer Ingelheim has announced that the Center for Drug Evaluation (CDE) of...
Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits
Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...
Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts
Shenzhen based biopharmaceutical company Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the...
Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...
China Medical System Partners with MabGeek for Innovative Drug MG-K10
China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...
BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062
BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...